Advertisement
Document › Details
Roche. (12/29/23). "Press Release: Roche Enters into a Definitive Agreement to Acquire LumiraDx's Point of Care Technology Combining Multiple Diagnostic Modalities on a Single Platform". Basel.
Organisation | Roche Diagnostics (Group Division) | |
Group | Roche (Group) | |
Organisation 2 | LumiraDx Ltd. | |
Group | LumiraDx (Group) | |
Product | point-of-care diagnostic device | |
Product 2 | diagnostic technology | |
Index term | LumiraDx–Roche: investment, 202312– acquisition $295m + $55m milestones of parts of LumiraDx Group related to innovative PoC technology | |
Person | Sause, Matt (Roche 202303 CEO of Roche Diagnostics) | |
Person 2 | Ameye, Veronique (LumiraDx 202312 CEO) | |
> The transformative point of care solution will complement Roche’s centralised diagnostics portfolio across Clinical Chemistry, Immunochemistry, Coagulation and Molecular, and across multiple disease areas
> LumiraDx’s technology integrates multiple Point of Care tests on a simple to use single instrument and brings more affordable and accessible testing to patients worldwide
> Under the terms of the agreement, Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the entry into a definitive agreement to acquire select parts of the LumiraDx group (NASDAQ GS: LMDX) related to LumiraDx’s innovative Point of Care technology. Following closing of the transaction, which is expected by mid-2024, the acquired entities will be fully integrated into Roche Diagnostics.
“The addition of the LumiraDx technology to our diagnostics portfolio will enable us to transform testing at the point of care.” said Matt Sause, CEO Roche Diagnostics. “LumiraDx has developed a highly versatile platform that delivers strong performance across multiple disease areas and technologies. We believe this will enable better patient access to timely results in decentralised healthcare settings worldwide.”
Veronique Ameye, Chief Executive Officer of LumiraDx added, “Since our founding, we have sought to transform community-based healthcare by consolidating multiple Point of Care tests on a single instrument. We are thrilled that Roche will continue this important work and increase its reach around the globe. This will enable more patients to get fast and easy access to better diagnostic testing.”
The transaction is part of Roche’s vision to enable more patient-centric healthcare, with Point of Care solutions that span the entire patient journey – from the home, pharmacy and general practitioner’s office to the emergency room, intensive care unit and beyond. The acquired technology platform offers a wide range of immunoassay and clinical chemistry tests, with great potential for additional high medical value tests in the future. These are capable of being stored at room temperature which enables convenient handling in a range of decentralised healthcare settings. By leveraging its extensive global reach and established affiliate network, Roche will be able to drive access to timely, accurate diagnostic results when and where patients need them most.
Terms of the acquisition
The transaction is subject to certain conditions including antitrust and regulatory approvals.
Under the terms of the agreement, at the closing of the transaction Roche will pay a purchase price of USD 295 million (subject to customary closing adjustments) and an additional payment of up to USD 55 million for the reimbursement of amounts to fund the Point of Care technology platform business until the closing of this acquisition. The transaction is part of a pre-packaged UK administration sale, with the full support of LumiraDx group’s senior secured lender.
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavour to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the fifteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
Hans Trees, PhD
Phone: +41 79 407 72 58
Nathalie Altermatt
Phone: +41 79 771 05 25
Simon Goldsborough
Phone: +44 797 32 72 915
Karsten Kleine
Phone: +41 79 461 86 83
Nina Mählitz
Phone: +41 79 327 54 74
Kirti Pandey
Phone: +49 172 6367262
Dr. Rebekka Schnell
Phone: +41 79 205 27 03
Sileia Urech
Phone: +41 79 935 81 48
Roche Investor Relations
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
Record changed: 2024-01-31 |
Advertisement
More documents for Roche (Group)
- [1] Roche. (4/11/24). "Press Release: Roche Granted FDA Breakthrough Device Designation for Blood Test to Support Earlier Alzheimer's Disease Diagnosis". Basel....
- [2] Freenome, Inc.. (2/15/24). "Press Release: Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection". South San Francisco, CA....
- [3] PathAI Inc.. (2/13/24). "Press Release: PathAI Announces Exclusive Collaboration with Roche Tissue Diagnostics to Advance AI-enabled Interpretation for Companion Diagnostics". Boston, MA....
- [4] Repare Therapeutics Inc.. (2/12/24). "Press Release: Repare Therapeutics to Regain Global Rights to Camonsertib". Cambridge, MA & Montréal....
- [5] Hookipa Pharma Inc.. (1/29/24). "Press Release: Hookipa Pharma Provides Update on Business Priorities and Oncology Partnership Programs". New York, NY & Vienna....
- [6] Repare Therapeutics Inc.. (1/25/24). "Press Release: Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment". Cambridge, MA & Montréal....
- [7] Roche Deutschland Holding GmbH. (1/10/24). "Press Release: Prof. Hagen Pfundner wird zum 1. Mai 2024 Vorsitzender der Roche Deutschland Holding GmbH"....
- [8] Remix Therapeutics, Inc.. (1/3/24). "Press Release: Remix Therapeutics Enters Collaboration with Roche for the Discovery and Development of Small Molecule Therapeutics Modulating RNA Processing". Watertown, MA....
- [9] MediLink Therapeutics (Suzhou) Co., Ltd.. (1/2/24). "Press Release: MediLink Therapeutics Announces Worldwide Collaboration and License Agreement with Roche to Develop Next-generation Antibody Drug Conjugate in Oncology". Suzhou....
- [10] Roche. (12/4/23). "Press Release: Roche Enters into a Definitive Merger Agreement to Acquire Carmot Therapeutics, including Three Clinical Stage Assets with Best-in-class Potential in Obesity and Diabetes". Basel....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top